GADD45α Mediated Cell Cycle Inhibition Is Regulated By P53 In Bladder Cancer

Na Han,1,2,* Fang Yuan,2,3,* Peng Xian,2,3,* Nan Liu,2,3 Jianmin Liu,4 Haiyan Zhang,1,2 Huayong Zhang,4,5 Kai Yao,6 Gangjun Yuan2,3

1Health Examination and Oncology Screening Center, Chongqing University Cancer Hospital, Chongqing 400030, People’s Republic of China; 2Department of Urology, Chongqing University Cancer Hospital, Chongqing 400030, People’s Republic of China; 3Department of Otolaryngology Head and Neck Surgery, People’s Hospital of Deyang, Deyang 618000, People’s Republic of China; 4Department of Thyroid and Breast Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, People’s Republic of China; 5Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China

*These authors contributed equally to this work

Background: Bladder cancer (BC) is one of the most prevalent malignancies of the genitourinary system, yet the underlying mechanism of BC progression still remains unclear. Growth arrest and DNA damage-inducible 45 alpha (GADD45α) is a repressive gene implicated in cell cycle regulation, as well as in human cancers development. However, its role in BC remains to be determined.

Methods: First, quantitative real-time polymerase chain reaction (PCR) and Western blot assays were used to detect GADD45α expression in BC tissues and adjacent non-tumor tissues, as well as in bladder cancer cell lines, respectively. Then, cell counting kit-8 (CCK-8) assays, colony formation assays, and flow cytometry assays were used to measure the ability of cell growth, proliferation and cell cycle distribution. Lentiviral infection technology was used to increase gene expression, while siRNA interfering technology was used to knockdown gene expression. Finally, nude mice were used to construct tumor-burdened models in vivo by injecting tumor cells subcutaneously.

Results: PCR results showed that the level of GADD45α mRNA and protein levels were lower in BC tissues than in adjacent normal tissues. After increasing GADD45α expression, both the ability of growth and proliferation of BC cells were seriously impaired. Additionally, the upregulation of GADD45α expression resulted in BC cell cycle in G2/M and S phases in a p53-regulated pathway.

Conclusion: GADD45α-mediated cell cycle inhibition is regulated by p53 in bladder cancer cells.

Keywords: GADD45α, bladder cancer, cell cycle, p53, proliferation

Introduction

Bladder cancer (BC) is still one of the most risky malignancies affecting the genitourinary system, especially in Chinese people, with an increased risk of both mortality and mobility according to a clinical data in 2015.1 It is reported that there were 74,690 new BC cases, leading to 25,580 deaths in 2014.2 Much efforts has been devoted to studying BC progression. However, the molecular mechanism still remains to be determined. Thus, there is an urgent need to explore how BC develops and progresses.

Our previous work showed that growth arrest and DNA damage-inducible 45 alpha gene (GADD45α) may play a repressive role in BC cell proliferation by delaying cell cycle progression in the G2/M phase.3 GADD45α was first found and defined by Fornace et al in 1989 when researchers found that some mRNAs were increased after exposure to a variety of exogenous and endogenous stresses associated with growth arrest, including ultraviolet (UV) radiation.4 GADD45α belongs
to a highly conserved three-gene GADD family with two other members GADD45b and GADD45g. These genes were first cloned from Chinese hamster ovary (CHO) cells after exposure to UV radiation and functioned as a subset of transcription factors. 5–7 GADD45a protein localizes within the nucleus and interacts with cdc2/cyclinB1 kinases to inhibit cell cycle progression in the G2/M and S phase. 8–10 In addition, GADD45a is involved in DNA damage, apoptosis, cell injury, and other growth regulatory processes.

Because of its repressive activity in cell proliferation, GADD45a is believed to have a negative role in carcinogenesis. Hollander et al reported that knockdown of GADD45a in a mouse lung cancer model led to higher malignancy tumors and an increased risk of multiple tumor types. 11 Also, GADD45a was found to suppress the tumor angiogenesis by downregulating VEGFα expression via blocking the mTOR/STAT3 pathway. 12 However, the role of GADD45a in BC has not yet been explored.

Thus, in this study, we investigated the expression of GADD45a in BC tissues and cells to reveal its potential role in BC progression using a series of in vivo and in vitro experiments.

Materials And Methods

BC Tissues

Two groups of six paired fresh MIBC tissues and adjacent non-tumor tissues from the same patient were stored in liquid nitrogen for Western blot and quantitative RT-PCR assays. Clinical data of the six patients are shown in Table 1. All samples were classified according to the 2010 American Joint Committee on Cancer TNM classification. All BC tissues were histologically identified to be urothelial carcinomas. The Medical Ethics Committee of The Sun Yat-Sen University Cancer Center approved this study, and all patients provided their consent to use their clinical specimens.

Cell Culture

UCB cell lines, T24, BIU, UMUC3, and 5637, were obtained from the American Type Culture Collection in 2003. Stocks were prepared after passage 2 and stored in liquid nitrogen. These cell lines were authenticated by the China Center for Type Culture Collection of Wuhan University and Mycoplasma testing was done by the authors before initiating this study. All experiments were performed with cells of < 8 passages. Cell lines 293-T and SV-HUC-1 were purchased from the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. BC cell lines and normal urothelial cell line SV-HUC-1 were cultured in RPMI 1640 media, while UMUC3 and 293-T cell lines were cultured in DMEM media. All media were supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/mL) and streptomycin (100 μg/mL) (all three materials were from Gibco, ThermoFisher, USA) at 37 °C in 5% CO₂ atmosphere.

Cell Viability Assay

Cell viability was measured according to the manufacture’s protocol of CCK-8 (cell counting kit-8) reagent (Dojindo, Kumamoto, Japan). Briefly, a total of 5×10³ cells/well were seeded in 96-well plates to incubate for cell viability measurements at different time points of 12 h, 24 h, 36 h, 48 h, 60 h, and 72 h. The CCK-8 kit was added per well to co-incubate for 2–4 h before detection. Absorbance was measured at 450 nm in each well with a microplate spectrophotometer (SpectraMax M5; Molecular Devices, Sunnyvale, CA, USA).

Colony Formation Assay

Approximately 500 cells were seeded into each well in a six-well plate and incubated for 5–7 days. Colonies were fixed with methanol for 30 min and stained with 0.1% crystal violet for 1 h.

Table 1 Clinical Information Of 6 Cases Whose Tissues Were Used For qRT-PCR And Western Blot Assay

<table>
<thead>
<tr>
<th>NO.</th>
<th>GENDER</th>
<th>AGE (YEAR)</th>
<th>STAGE</th>
<th>GRADE</th>
<th>SMOKING</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>57</td>
<td>T2</td>
<td>G3</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>63</td>
<td>T2</td>
<td>G3</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>65</td>
<td>T3</td>
<td>G3</td>
<td>No</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>47</td>
<td>T2</td>
<td>G3</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>72</td>
<td>T1</td>
<td>G3</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>67</td>
<td>T2</td>
<td>G3</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Abbreviations: M, male; F, female.
Cell Cycle Analysis
Determined cells were harvested and then washed with cold PBS for three times, followed by fixing the cells in chilled 70% ethanol overnight at 4°C. A cell cycle analysis kit (Beyotime, Shanghai, China) was used to measure cell cycle distribution following the manufacturer’s protocol. The cell cycle determination was performed using a flow cytometry system (MoFlo XDP, Beckman Coulter, CA, USA). The relative level of gene expression was expressed as ΔΔCt = Ctgene - Ctreference, and the 2-ΔΔCt method was used to calculate the fold change of gene expression. Tubulin-α was used as a control and for normalization. The primer sequences are as follows: for GADD45a, forward, 5'-TCGTGAATGGAAGGATGG-3'; reverse, 5'-AGGTTTTGGCTTGGGTCA-3'; and for GAPDH, forward, 5'-CCGAGTCACCGATTGTCGTTAT-3' and reverse, 5'-AGGCC TTCTCATGTTGGTGAGAC-3'.

Western Blot Analysis
Determined cells were harvested and lysed to obtain protein extracts for further electrophoresis analysis. For fresh and frozen BC tissues, they were ground in liquid nitrogen and then lysed for obtaining protein lysates. All protein extracts were separated on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels, and electro-transferred to a polyvinylidene fluoride (PVDF) membrane at 250 mA for 2 h at room temperature. Then the membrane was blocked in 5% bovine serum albumin or defatted milk for 1 h at room temperature and incubated overnight at 4°C with primary antibodies (GADD45a, Tubulin-α and GAPDH antibodies were from Proteintech Group Inc., Rosemont, IL, USA; p53, cdc2, cyclinB1, CDK2, CDK4 and cyclinD1 were from Cell Signaling Technology, Danvers, MA, USA). The membrane was washed three times with phosphate-buffered saline (PBS) containing 0.1% Tween (PBST), followed by incubation with a secondary antibody for 1 h at room temperature. The signal was measured using an enhanced chemiluminescence (ECL) detection system (Tanon, Shanghai, China).

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Assay
The frozen tissues were ground in liquid nitrogen, and total RNA was extracted using TRIzol reagent (Invitrogen Life Technologies, USA) according to the manufacturer’s recommendations. Approximately 1 μg of RNA was used in the manufacturer’s recommendations for primer synthesis using random primers. A 15μL reaction system, which included the GADD45a specific primers, cDNA, and SYBR Green PCR mixture (Applied Biosystems), was prepared for amplification of the GADD45a cDNA. The qRT-PCR reaction conditions were as follows: initial denaturation at 95°C for 30 s, followed by annealing at 55°C for 1 min, and extension for 1 min at 72°C, for a total of 30 cycles. The process was performed in a triplicate on an ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA, USA). The relative level of gene expression was expressed as ΔΔCt = Ctgene - Ctreference, and the 2-ΔΔCt method was used to calculate the fold change of gene expression. Tubulin-α was used as a control and for normalization. The primer sequences are as follows: for GADD45a, forward, 5'-TCGTGAATGGAAGGATGG-3'; reverse, 5'-AGGTTTTGGCTTGGGTCA-3'; and for GAPDH, forward, 5'-CCGAGTCACCGATTGTCGTTAT-3' and reverse, 5'-AGGCC TTCTCATGTTGGTGAGAC-3'.

Overexpression Experiment
A lentivirus for GADD45a and p53 overexpression was purchased from HanBio (Shanghai, China). The virus vector was pHBLV-CMVIE-Zs Green-T2A-Puro. The final virus titer of overexpressing lentivirus and negative control virus was 2×10⁸ PFU/mL. T24 cells were transfected with the lentivirus to overexpress GADD45a and p53 premixed with lipofectamine 2000 (Invitrogen, USA). Stable cells were screened with puromycin (Gibco, Invitrogen, Darmstadt, Germany) at the concentration of 2 μg/mL for two weeks.

Xenograft Assay
Four-week-old Balb/c female nude mice were purchased from Charles River Laboratories (Beijing, China). The Animal Ethics Committee of Sun Yat-sen University, Guangzhou, China approved all animal experiments performed in this study. The welfare of the animals was guaranteed under the criteria of the “Laboratory Animal Management Regulations in China”. Mice were randomly divided into 2 groups with 6 mice. A total of 5×10⁵ T24 cells (control and overexpressing-GADD45a RNA) were subcutaneously inoculated into the right flank of the mice. The weight and volume of the tumors were determined at the end of the study. The following formula was used to measure tumor volume: Tumor volume = 1/2L × W², where L stands for the length and W is the width. All animal experiments were approved by the Animal Ethics Committee of Sun Yat-sen University cancer center.

Results
GADD45a Expression In BC And Adjacent Non-tumor Tissues
To determine the expression of GADD45a in BC, fresh tumor tissues and adjacent normal tissues were collected to obtain cellular proteins for further Western blots and quantitative PCR analysis. As shown in Figure 1A, GADD45a protein levels in BC tissues were lower than levels in the
adjacent normal tissues. Subsequent qRT-PCR assay in these paired tissues revealed that GADD45a mRNA was decreased in tumor tissues when compared to the adjacent non-tumor tissues (0.252 ± 0.063 vs. 1, p < 0.001. Figure 1B). Both assays indicated that GADD45a was down-regulated in BC tissues.

GADD45a Protein Expression In BC Cell Lines

Because of GADD45a expression changes between BC tissue and surrounding tissues, we also characterized GADD45a expression changes in between several BC cell lines and the normal urothelial cell line SV-HUC-1. As expected, GADD45a was downregulated in BC cells compared to SV-HUC-1 cells (Figure 1C).

Upregulation Of GADD45a Inhibits BC Cell Growth And Proliferation

To determine the role of GADD45a in BC cell growth, stable highly expressing GADD45a T24 cells were constructed. The CCK-8 kit was applied to detect the growth rate of BC cells. As shown in Figure 2A, increasing GADD45a expression decreased BC cell growth. In addition, it led to significantly fewer cell colonies than the control in two cell lines T24 and 5637 (T24, p = 0.032; 5637, p = 0.027) (Figure 2B). Theses results indicated that upregulation of GADD45a impairs BC growth and proliferation.

Upregulation Of GADD45a Inhibits BC Cell Cycle Progression In G2/M And S Phase

Since reports indicate that GADD45a interacts with cdc2/cyclinB1 kinases to delay cell cycle progression in the G2/M and S phase,9,10 we tested whether GADD45a has a similar inhibitory effect on the BC cell cycle using a flow cytometry assay. Results indicated that upregulation of GADD45a resulted in cell cycle arrest in the G2/M and S phase by increasing the percentage of cells in the G2 and S phase, and decreasing the percentage of cells in the G1 phase (Figure 3A). Meanwhile, G2-M transition related kinases cdc2 and cyclinB1 were dramatically decreased, whereas G1-S transition related CDK2, CDK4 and cyclinD1 were unchanged (Figure 3B).

GADD45a Mediated BC Cell Cycle Inhibition Is P53-regulated

GADD45a was the first described stress gene that is transcriptionally regulated by p53, a well-known repressive gene that is commonly downregulated in many phenotypes of human cancers.13 This information suggests that p53 may play a regulatory role in GADD45a-induced cell cycle inhibition.14 We found that p53 was downregulated in T24 cells compared to normal SV-HUC-1 cells (Figure 3C). Deletion of p53 would decrease GADD45a expression in SV-HUC-1 cells (Figure 3D). Nevertheless, increasing p53

---

**Figure 1** GADD45a expression in bladder cancer (BC). (A) Western blot analysis showed that GADD45a protein was downregulated more in BC tissues than in adjacent non-tumor tissues. (B) The result of quantitative real-time PCR detection showed that the level of GADD45a mRNA was significantly lower in BC tissues than adjacent normal tissues. Histograms display the mean number of colonies, and the number of colonies was shown as the mean ± SD of three independent experiments. (C) Western blot assay in BC cell lines found that GADD45a was downregulated in BC cell lines comparing to normal urothelial SV-HUC-1 cells.

Abbreviations: T, tumor tissues; N, normal tissues.
expression has contributed to elevated GADD45a expression, as well as to similar effects on cell cycle distribution like increasing GADD45a expression (Figure 3E and F). Overall, these results suggest that p53 positively regulates GADD45a expression and GADD45a-mediated cell cycle inhibition.

**Upregulation Of GADD45a Inhibits BC Cell Growth In Vivo**

To validate the inhibitory role of GADD45a in BC cell proliferation, tumor burdened mice were constructed by injecting BC cells subcutaneously. The results showed that mice with highly expressing GADD45a cells generated smaller tumors than control mice (Figure 4A). The volumes of tumors, as well as the weight of mice, were clearly recorded every 2 days after injection of BC cells (Figure 4B and C). At the end of the study, mice were sacrificed by cervical dislocation, followed by isolation of the tumors to count tumor volumes and weight (Figure 4D and E). The result showed that the volumes of tumors in mice injected with highly expressing GADD45a cells were significantly smaller than the control (137.86 ± 7625 vs. 845.57 ± 201.37, p < 0.001). The tumor weights (314.83 ± 59.57 vs. 527.83 ± 10.64, p < 0.001) were also significantly smaller than the control. These results indicated that upregulating GADD45a significantly inhibits tumor growth in vivo.

**Discussion**

A series of cellular responses with regulators and effectors are involved in responding to genotoxic stress including genotoxic, physiological, and oncogenic stimuli. Evidence indicates that GADD45a plays a critical role as a sensor in cellular stress responses. In addition, our previous work suggested a repressive role of GADD45a in BC cell cycle...
progression. Thus, it is meaningful to study GADD45a for BC treatment.

GADD45a was the first identified member of the GADD45 family, which contains two other members GADD45b and GADD45y. The GADD45 family was the 45th member of a collection of cDNA clones after cellular stress stimuli such as ultraviolet radiation as well as other growth cessation signals. All three members shared highly conserved sequence homology and were implicated in similar cellular responses often associated with stress signaling and other growth regulatory pathways. GADD45a was first reported and described as a stress-induced protein associated with growth arrest and stimulation of DNA-repair, as well as apoptosis and cell cycle inhibition. GADD45a implicated regulatory pathways are complicated and broad, with p38 and JNK stress mitogen-activated protein kinases (MAPK) as well as BRCA1, FOXOA3 and ATF4 being involved in the regulation of GADD45a expression. In the cellular nucleus, GADD45a protein interacts with a variety of proteins such as cdc2 and cdc2-cyclinB1 complex subsequently,

**Figure 3** Upregulation of GADD45a delays BC cell cycle progression in the G2/M and S phase. (A) Flow cytometry analysis in T24 and 5637 cells showed that upregulation of GADD45a inhibited cell cycle progression in G2/M and S phase. Histograms display the mean number of colonies, and the number of colonies was shown as the mean ± SD of three independent experiments, p <0.05 represents significance. (B) Western blot result showed that cdc2 and cyclinB1 were upregulated in highly expressing GADD45a cells, whereas CDK2, CDK4 and cyclinD1 were unchanged. (C) Western blotting showed that GADD45a expression was higher in normal urothelial SV-HUC-1 cells than in T24 cells. (D) Knockdown of p53 in SV-HUC-1 cells decreases GADD45a expression. (E) Upregulating p33 expression elevated GADD45a protein expression in T24 cells. (F) Upregulation of p53 inhibited T24 cell cycle progression in G2/M and S phase. Histograms display the mean number of colonies, and the number of colonies was shown as the mean ± SD of three independent experiments, p <0.05 represents significance.
participating in G2 checkpoint mechanisms and consequently inhibiting cell cycle progression in the G2/M phase.\textsuperscript{8,10,17}

Because GADD45a inhibits DNA-repaired cell proliferation, it is thought to be a tumor suppressor of human cancers including breast cancer, prostate cancer, and gastric cardia adenocarcinoma.\textsuperscript{18–21} It is reported that GADD45a is a direct target of the tumor suppressor FOXO3A, by which way that FOXO3a binds to the GADD45a promoter and induces GADD45a transcription.\textsuperscript{22} In addition, other tumor suppressor genes such as activating transcription factor-4 (ATF-4), APRIL and BRCA1 also play critical roles in GADD45a-mediated cell cycle inhibition.\textsuperscript{23–25}

In this study, we detected the expression of GADD45a in BC tissues and found that GADD45a was downregulated in BC tissues and cells, suggesting potential suppression of GADD45a in BC development. This was validated later when we found that BC cell growth and proliferation were impaired when GADD45a expression increased. Thus, reducing GADD45a expression may contribute to BC development and progression.

GADD45a positively participates in the cell cycle checkpoint mechanism of cell cycle and it displaces PCNA (proliferating cell nuclear antigen) from the cyclinD1 complex to delay the cell cycle in the S phase or in the G2/M phase by interacting with cdc2/cyclinB1.\textsuperscript{13,26} Consistent with other studies, our results indicated that increasing GADD45a expression delayed the BC cell cycle in the G2/M and S phases, accompanied with a reduction in cdc2/cyclinB1 activities.

P53 is a well-known and widely inactivated protein in many phenotypes of tumors, and it positively regulates GADD45a expression and GADD45a-mediated cell cycle inhibition. In addition, the p53-mediated GADD45a cell cycle regulation requires p38 activation by directly phosphorylating p53’s Ser46 site.\textsuperscript{27,28} In wild BC cells, p53 was downregulated. However, when p53 expression increased, GADD45a expression was upregulated and the BC cell cycle was subsequently delayed in the G2/M and S phase. This result supports that GADD45a-mediated cell cycle was p53-regulated.

**Ethical Approval**

Our study was approved by the Ethics Committee of Sun Yat-Sen University Cancer Center, Guangzhou, China.
Conclusion
In this study, we provided basic evidence that GADD45a was downregulated in BC, and GADD45a functions as a suppressor in BC progression by delaying cell cycle progression in a p53-regulated manner. Our study also suggested that GADD45a might become a potential target for treating BC in future.

Acknowledgments
This work was supported by grants from the Natural Science Foundation of Chongqing (No. cstc2019jcyj-msxmX0420), the Sun Yat-sen University Cancer Center Medical Scientist Training Program (No. 14zxqk08), the Chongqing Municipal Science and Technology Bureau and Health Bureau Joint Medical Research Project (No. 2018MSXM033), and the Performance Incentive and Guidance Program of Chongqing Scientific Research Institutions (cstc2017jxj1130012).

Disclosure
The authors report no conflicts of interest in this work.

References